Misonix receives donation from anonoymous patient to buy SonicOne ultrasonic wound care system

Sep 15 2009

Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.

The donation was made by a patient of Christus St. Vincent's Wound and Hyperbaric Center, where she was being treated for chronic, non-healing wounds over a lengthy period of time. During the period of clinical evaluation of the SonicOne, prior to possible purchase, the patient was treated with the SonicOne System, and, in a subsequent visit, it was noted that there was a noticeable improvement in the wound healing process. The patient wanted to move forward with additional SonicOne treatments, but was informed that the clinical evaluation was complete and a decision on purchasing the system would be made when funds became available. The patient inquired as to where a donation might be made so that the equipment could be available for her next appointment. A sizable donation was received by the St. Vincent Hospital foundation the next day, a purchase was made from the Company, and the SonicOne was delivered and installed within one week; in time for the patient's next appointment.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is always pleased to receive testimonials directly from patients who benefit from our products and technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We have always believed that our wound care product platform can make an important contribution to improving patient outcomes and are gratified when real life situations justify our investment in product development and clinical applications."